Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer

Core Insights - Sana Biotechnology, Inc. has appointed Dr. Dhaval Patel as Executive Vice President and Chief Scientific Officer, bringing extensive experience in research and drug development [1][2] - Dr. Patel has a proven track record, having contributed to the advancement of 10 FDA-approved treatments and has expertise in immunology and autoimmune diseases, which aligns with Sana's clinical pipeline focus [2][3] - The company is currently conducting four clinical trials across seven indications, including B-cell mediated autoimmune diseases and type 1 diabetes, indicating a strong commitment to innovative therapies [3] Company Overview - Sana Biotechnology is dedicated to creating engineered cells as medicines, aiming to repair and control genes and replace missing or damaged cells [4] - The company operates in multiple locations including Seattle, WA, Cambridge, MA, South San Francisco, CA, Bothell, WA, and Rochester, NY [4]